Tumor Antigens and Antigen-Presenting Capacity in Breast Cancer
- 1 January 2002
- journal article
- Published by S. Karger AG in Pathobiology
- Vol. 70 (6), 324-332
- https://doi.org/10.1159/000071272
Abstract
Cancer cells frequently express antigens capable of being recognized by the host immune system; however, any resultant immune response is often ineffective. This may be related in part to tumor-induced defects in antigen presentation. We screened for dendritic cell infiltration, tumor MHC II expression and associated lymphocytic reaction in the context of three established breast tumor antigens. Forty primary breast tumors were evaluated by immunohistochemical techniques for expression of her2/neu, p53, and MUC1 and MHC class II molecules. Twenty-five samples were further analyzed for p53 mutations by PCR-SSCP analysis and DNA sequencing. The phenotype of tumor-infiltrating inflammatory cells was evaluated using the following markers: CD1a, MHC Class II, CD3, CD45, and CD45RO. Tumors with p53 mutations and overexpression, but not her2/neu or MUC1 overexpressing tumors, more frequently harbored marked CD1a+ dendritic cell infiltrates. An overall correlation between CD1a+ cell infiltrates and HLA class II expression on tumor cells (p = 0.0008) was also observed and these tumors had greater CD45RO+ lymphocytic infiltrates. In breast cancer, p53 mutations may present a more visible signal to the immune system and hence provide a better target for immunotherapy. Infiltrating CD1a positive cells are associated with a more dense tumor lymphocytic infiltrate and tumor cell expression of MHC II molecules.Keywords
This publication has 14 references indexed in Scilit:
- HLA-DR and β2microglobulin expression in medullary and atypical medullary carcinoma of the breast: histopathologically similar but biologically distinct entitiesJournal of Clinical Pathology, 2000
- Infiltrating dendritic/Langerhans cells in primary breast cancerBreast Cancer Research and Treatment, 2000
- In Breast Carcinoma Tissue, Immature Dendritic Cells Reside within the Tumor, Whereas Mature Dendritic Cells Are Located in Peritumoral AreasThe Journal of Experimental Medicine, 1999
- The Makings of a Tumor Rejection AntigenImmunity, 1999
- Lack of class II transactivator causes severe deficiency of HLA-DR expression in small cell lung cancerThe Journal of Pathology, 1999
- Peptide-based cancer vaccinesCurrent Opinion in Immunology, 1996
- Tumor Antigens Recognized by T LymphocytesAnnual Review of Immunology, 1994
- Natural history of HLA expression during tumour developmentImmunology Today, 1993
- Immunohistochemical study of p53 expression in endometrial carcinomas: correlation with markers of proliferating cells and clinicopathologic featuresInternational Journal of Gynecologic Cancer, 1993
- Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay.The Journal of Experimental Medicine, 1976